Platelet aggregation inhibitors

Details Platelet aggregation inhibitors Platelet aggregation inhibitors

1995-06-07

1998-05-26

Davenport, Avis M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 14, 514 15, 514 16, 514 17, 514 18, 530317, 530326, 530327, 530328, 530329, 530330, A61K 3800, A61K 3802, C07K 500, C07K 700

Patent

active

057564515

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

This invention relates to a group of peptides which are, or are related to, platelet aggregation inhibitors isolated and purified from various snake venoms. These peptides are useful as therapeutic agents for the treatment of, and prevention of, platelet-associated ischemic disorders. More specifically, the invention concerns peptides which block specific receptors for adhesive proteins involved in platelet adherence and aggregation. Furthermore, this invention describes methods for detecting and purifying said polypeptides to substantial homogeneity from snake venoms, as well as processes for using the primary amino acid sequences of these polypeptides to prepare active peptides both synthetically and through use of recombinant DNA methods.


BACKGROUND ART

Heart disease is the primary cause of death in most western societies. Death from heart disease is often induced by platelet-dependent ischemic syndromes which are initiated by atherosclerosis and arteriosclerosis and include, but are not limited to, acute myocardial infarction, chronic unstable angina, transient ischemic attacks and strokes, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism, restenosis and/or thrombosis following angioplasty, carotid endarterectomy, anastomosis of vascular grafts, and chronic cardiovascular devices (e.g., in-dwelling catheters or shunts "extracorporeal circulating devices"). These syndromes represent a variety of stenotic and occlusive vascular disorders thought to be initiated by platelet activation either on vessel walls or within the lumen by blood-borne mediators but are manifested by platelet aggregates which form thrombi that restrict blood flow.
Numerous studies have contributed to an understanding of the mechanism of platelet aggregation and thrombus formation. Platelets respond to a variety of blood vessel injuries, such as narrowing of the lumen, plaque formation, and the presence of foreign bodies (e.g., catheters) and the like. The response of platelets to these injuries is a sequence of events including platelet adherence and activation, and the release of platelet granular components; including potent cellular mitogenic factors. The activated platelet aggregates induce the formation of fibrin, which further stabilizes the thrombus.
Much is now known about mechanisms regulating these responses. Although unstimulated platelets contain receptors for several adhesive proteins including laminin (VLA 2, VLA 6) and collagen (VLA 2, GPIV, others), the initial attachment of platelets to subendothelium is believed to be mediated by the binding of platelet membrane glycoprotein (GP) Ib to the immobilized von Willebrand factor. Subsequent platelet activation can be initiated by one or more of the known physiological agonists including: ADP, epinephrine, thrombin, collagen, and thromboxane A2.
Platelet aggregation is mediated by GP IIb-IIIa complex on the platelet membrane surface. GP IIb-IIIa exists on the surface of unstimulated platelets in an inactive form. When platelets are activated by adhesion and the physiological agonists, the GP IIb-IIIa also becomes activated such that it becomes a receptor for fibrinogen (Fg), von Willebrand Factor (vWF), and fibronectin (Fn) (see Phillips et al., Blood (1988) 71:831-843); however, it is the binding of fibrinogen and/or von Willebrand factor that is believed to be principally responsible for platelet aggregation and thrombus formation in vivo. Therefore, substances which specifically inhibit the binding of fibrinogen or von Willebrand factor to GP IIb-IIIa inhibit platelet aggregation and could be candidates for inhibiting thrombus formation in vivo.
Platelet GP IIb-IIIa is now known to be a member of a superfamily of structurally related adhesive protein receptors known collectively as the "integrins." Like GP IIb-IIIa, all integrins known to date are two subunit molecules with a larger alpha-subunit (e.g., GP IIb) and a smaller beta-subunit (e.g., GP IIIa). There is a high degree of homology between the known sequences of the in

REFERENCES:
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4614517 (1986-09-01), Ruoslahti et al.
patent: 4652639 (1987-03-01), Stabinsky
patent: 4661111 (1987-04-01), Ruoslahti et al.
patent: 4661471 (1987-04-01), Hawiger et al.
patent: 4683291 (1987-07-01), Zimmerman et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4857508 (1989-08-01), Adams et al.
patent: 4992463 (1991-02-01), Troeng et al.
patent: 5023233 (1991-06-01), Nutt
patent: 5100875 (1992-03-01), de Rotrou
patent: 5338723 (1994-08-01), Nutt
patent: 5340798 (1994-08-01), Nutt
patent: 5374622 (1994-12-01), Nutt
Charon, et al., Synthetic Peptide with Antithrombotic Activity, Peptides, Chemistry, Structure and Biology, Proceedings of the Eleventh American Peptide Symposium, Jul. 9-14, 1989, La Jolla, CA, pp. 82-83.
Ginsberg, et al., Inhibition of Fibronectin Binding to Platelets by Proteolytic Fragments and Synthetic Peptides Which Support Fibroblast Adhesion, The Journal of Biological Chemistry, 260(7):3931-3936 (1985).
Hanson et al., Baboon Models of Acute Arterial Thrombosis, Thrombosis and Haemostatis, 58(3):801-805 (1987).
Hanson et al., Platelet Interaction with Dacron Vascular Grafts, Arteriosclerosis, 5:595-603 (Nov./Dec. 1985).
Huang et al., Mechanism of Action of the Platelet Aggregation Inhibitor Purified from Agkistrodon Halys (Mamushi) Snake Venom, Toxicon, 22:243-252 (1984).
Huang et al., Characterization of a Potent Platelet Aggregation Inhibitor from Agkistrodon Rhodostoma Snake Venom, Biochimica et Byophysica Acta 22789, 925:248-257 (1987).
Kosugi, et al., Isolation of Platelet Aggregation Inhibitor from Trimesurus Flavoridis Snake Venom, The Snake, 17:117-123 (1985).
Kumagai, et al., Effect of Cyclic RGD Peptide On Cell Adhesion and Tumor Metastasis, Biochemical and Biophysical Research Communications, 117(1):74-82 (1991).
Musial, et al., Inhibition of Platelet Adhesion to Surfaces of Extracorporeal Circuits by Disintegrins, Circulation, 82(1):262-273 (1990).
Niewiarowski et al., Inhibition of Platelet Adhesion to Surfaces of Extracorporeal Circuit by RGD Containing Peptides from Viper Venoms, Thrombosis and Haemostasis, 62:319, Abstract No. 853 (1989).
Nutt, et al., Development of Novel, Highly Selective Fibrinogen Receptor Antagonists as Potentially Useful antithrombotic Agents, Peptide, Chemistry and Biology, Proceedings of the Twelfth American Peptides Symposium, Jun. 16-21, 1991, Cambridge, MA, pp. 914-916.
Nutt, et al., Structure- and Conformation-Activity Studies Leading to Potent Fibrinogen Receptor Antagonists Containing Arg-Gly-Asp, Peptides, pp. 784-786 (1990).
Ouyang et al., A Potent Platelet Aggregation Inhibitor Purified from Agkistrodon Halys (Mamushi) Snake Venom, Toxicon, 21(6):797-804 (1983).
Samanen, et al., Development of a Small RGD Peptide Fibrinogen Receptor Antagonist with Potent Antiaggregatory Activity in Vitro, J. Med. Chem. 34:3114-3125 (1991).
Scarborough, et al., Barbourin A GPIIb-IIIa-Specific Integrin Antagonist from the Venom of Sistrurus M. Barbouri, The Journal of Biological Chemistry, 266 (15):9359-9362 (1991).
Scarborough, Design of Potent and Specific Integrin Antagonists, J. Biol. Chem., 268:1066-1073 (1993).
Smith et al., Table 3.1 The Structures of the .alpha.-Amino Acids Commonly Found in Proteins, Principles of Biochemistry, 7th Edition, pp. 32-33, 1983, McGraw Hill.
Steiner et al., CA.sup.2+ --Dependent Binding of a Synthetic Arg-Gly-Asp (RGD) Peptide to a Single Site on the Purified Platelet Glycoprotein IIb-IIIa Complex, J. Biol. Chem., 264(22):13102-13108 (1989).
Ali et al., Structure-Activity studies Toward the Improvement of Antiaggregatory Activity of Arg-Gly-Asp-Ser (RGDS) Peptides: Chemistry, Structure and Biology (Proceedings of the 11th American Peptide Symposium), Marshall, G.R. and River, J.E. editors, ESCOM, Leiden (1990) pp. 94-96.
Bennett et al., Inhibition of Fibrinogen Binding Stimulated Human Platelets

Affiliated with

Also associated with

Rating

Platelet aggregation inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Platelet aggregation inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platelet aggregation inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1960012